HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer
Summary. Aim: UBC9 (E2) small ubiquitin-like modifier conjugating enzyme plays a key role in the post-translational modification of proteins named sumoylation. Defects in small ubiquitin-like modifier modification may contribute to breast carcinogenesis. In the present work, we examined UBC9&nbs...
Збережено в:
| Дата: | 2023 |
|---|---|
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
PH Akademperiodyka
2023
|
| Теми: | |
| Онлайн доступ: | https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-12 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Experimental Oncology |
Репозитарії
Experimental Oncology| id |
oai:ojs2.ex.aqua-time.com.ua:article-195 |
|---|---|
| record_format |
ojs |
| institution |
Experimental Oncology |
| baseUrl_str |
|
| datestamp_date |
2023-10-11T16:43:03Z |
| collection |
OJS |
| language |
English |
| topic |
breast cancer gene polymorphism high resolution melting method sumoylation UBC9 gene |
| spellingShingle |
breast cancer gene polymorphism high resolution melting method sumoylation UBC9 gene Bialik, P. Wysokinski, D. Slomka, M. Morawiec, Z. Strapagiel, D. Wozniak, K. HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| topic_facet |
breast cancer gene polymorphism high resolution melting method sumoylation UBC9 gene breast cancer gene polymorphism high resolution melting method sumoylation UBC9 gene |
| format |
Article |
| author |
Bialik, P. Wysokinski, D. Slomka, M. Morawiec, Z. Strapagiel, D. Wozniak, K. |
| author_facet |
Bialik, P. Wysokinski, D. Slomka, M. Morawiec, Z. Strapagiel, D. Wozniak, K. |
| author_sort |
Bialik, P. |
| title |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| title_short |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| title_full |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| title_fullStr |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| title_full_unstemmed |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| title_sort |
hrm screening of the ubc9 gene encoding the sumo-e2-conjugating enzyme — case-control study in breast cancer |
| title_alt |
HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer |
| description |
Summary. Aim: UBC9 (E2) small ubiquitin-like modifier conjugating enzyme plays a key role in the post-translational modification of proteins named sumoylation. Defects in small ubiquitin-like modifier modification may contribute to breast carcinogenesis. In the present work, we examined UBC9 genetic variation. Materials and Methods: UBC9 genetic variation was analyzed by using the high resolution melting (HRM) method. HRM study was conducted on 173–182 healthy women and 188–190 women with breast cancer. Results: During HRM screening, we analysed three known single-nucleotide polymorphisms in introns: rs4984806, rs909916 and rs909917, and one known single nucleotide polymorphism rs8063 in exon 7, in a non-coding region. The genotype frequencies for all polymorphisms were in accordance with Hardy — Weinberg equilibrium among the control subjects and breast cancer patients. The linkage disequilibrium analysis displayed that there was one polymorphism block, which consisted of three single nucleotide polymorphisms: rs909916, rs909917 and rs4984806. We identified two common haplotypes CCG and TTC, but we did not find significant differences in the distribution of these haplotypes between cases and controls. Conclusion: Our study showed no differences in the occurrence of indicated polymorphisms in the UBC9 gene in a group of healthy women compared to women with breast cancer. These results suggest that the polymorphisms of the UBC9 gene — rs4984806, rs909916, rs909917 and rs8063 can be not associated with breast cancer risk. |
| publisher |
PH Akademperiodyka |
| publishDate |
2023 |
| url |
https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-12 |
| work_keys_str_mv |
AT bialikp hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer AT wysokinskid hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer AT slomkam hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer AT morawiecz hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer AT strapagield hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer AT wozniakk hrmscreeningoftheubc9geneencodingthesumoe2conjugatingenzymecasecontrolstudyinbreastcancer |
| first_indexed |
2025-07-17T12:16:24Z |
| last_indexed |
2025-07-17T12:16:24Z |
| _version_ |
1850411134233870336 |
| spelling |
oai:ojs2.ex.aqua-time.com.ua:article-1952023-10-11T16:43:03Z HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer HRM screening of the UBC9 gene encoding the SUMO-E2-conjugating enzyme — case-control study in breast cancer Bialik, P. Wysokinski, D. Slomka, M. Morawiec, Z. Strapagiel, D. Wozniak, K. breast cancer, gene polymorphism, high resolution melting method, sumoylation, UBC9 gene breast cancer, gene polymorphism, high resolution melting method, sumoylation, UBC9 gene Summary. Aim: UBC9 (E2) small ubiquitin-like modifier conjugating enzyme plays a key role in the post-translational modification of proteins named sumoylation. Defects in small ubiquitin-like modifier modification may contribute to breast carcinogenesis. In the present work, we examined UBC9 genetic variation. Materials and Methods: UBC9 genetic variation was analyzed by using the high resolution melting (HRM) method. HRM study was conducted on 173–182 healthy women and 188–190 women with breast cancer. Results: During HRM screening, we analysed three known single-nucleotide polymorphisms in introns: rs4984806, rs909916 and rs909917, and one known single nucleotide polymorphism rs8063 in exon 7, in a non-coding region. The genotype frequencies for all polymorphisms were in accordance with Hardy — Weinberg equilibrium among the control subjects and breast cancer patients. The linkage disequilibrium analysis displayed that there was one polymorphism block, which consisted of three single nucleotide polymorphisms: rs909916, rs909917 and rs4984806. We identified two common haplotypes CCG and TTC, but we did not find significant differences in the distribution of these haplotypes between cases and controls. Conclusion: Our study showed no differences in the occurrence of indicated polymorphisms in the UBC9 gene in a group of healthy women compared to women with breast cancer. These results suggest that the polymorphisms of the UBC9 gene — rs4984806, rs909916, rs909917 and rs8063 can be not associated with breast cancer risk. Summary. Aim: UBC9 (E2) small ubiquitin-like modifier conjugating enzyme plays a key role in the post-translational modification of proteins named sumoylation. Defects in small ubiquitin-like modifier modification may contribute to breast carcinogenesis. In the present work, we examined UBC9 genetic variation. Materials and Methods: UBC9 genetic variation was analyzed by using the high resolution melting (HRM) method. HRM study was conducted on 173–182 healthy women and 188–190 women with breast cancer. Results: During HRM screening, we analysed three known single-nucleotide polymorphisms in introns: rs4984806, rs909916 and rs909917, and one known single nucleotide polymorphism rs8063 in exon 7, in a non-coding region. The genotype frequencies for all polymorphisms were in accordance with Hardy — Weinberg equilibrium among the control subjects and breast cancer patients. The linkage disequilibrium analysis displayed that there was one polymorphism block, which consisted of three single nucleotide polymorphisms: rs909916, rs909917 and rs4984806. We identified two common haplotypes CCG and TTC, but we did not find significant differences in the distribution of these haplotypes between cases and controls. Conclusion: Our study showed no differences in the occurrence of indicated polymorphisms in the UBC9 gene in a group of healthy women compared to women with breast cancer. These results suggest that the polymorphisms of the UBC9 gene — rs4984806, rs909916, rs909917 and rs8063 can be not associated with breast cancer risk. PH Akademperiodyka 2023-06-01 Article Article application/pdf https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-12 10.32471/exp-oncology.2312-8852.vol-42-no-2.14739 Experimental Oncology; Vol. 42 No. 2 (2020): Experimental Oncology; 130-134 Експериментальна онкологія; Том 42 № 2 (2020): Експериментальна онкологія; 130-134 2312-8852 1812-9269 10.32471/exp-oncology.2312-8852.vol-42-no-2 en https://exp-oncology.com.ua/index.php/Exp/article/view/2020-2-12/2020-2-12 Copyright (c) 2023 Experimental Oncology https://creativecommons.org/licenses/by-nc/4.0/ |